Ahamada Safna Mariyam Mubarak ali , Suchandra Sen
The study aims to assess the efficacy of topiramate in reducing migraine related disability and the intensity of pain. A prospective observational study was conducted in a multi specialty hospital for a period of eight months from June 2011 to March 2012. The disruption caused by migraine is assessed using MIDAS and Mc-Gill pain scale questionnaires. In a total of 100 patients’ recruited in the study 85 were females and 15 were males. The mean age of the study population was found to be 28.6(4.49) years. (There was a significant (p ≤ 0.01) improvement in the Migraine Disability Assessment Scale (MIDAS) and Mc-Gill pain scales in the final visit from the baseline. The mean MIDAS score of the final visit 7.25(1.87) from the baseline score 32.87(11.70) was found to be significant (p ≤ 0.01). The intensity of pain in the study population assessed using Mc-Gill pain scale (short form) showed a significant (p ≤ 0.01) reduction in the pain intensity in the final visit 8.56 (1.82) from the baseline 27.28 (6.88). This prospective study thus revealed Topiramate is efficacious in reducing migraine related disability, pain and also improve the ability to function in their daily lives. Individual patient care and patient counseling may improve patient compliance in migraine which leads to better therapeutic efficacy.
